March 13, 2024
by Ceci Connolly and Sami Inkinen
Unless you have been living under a rock, you likely have heard the names Ozempic, Wegovy or Mounjaro. Or perhaps been humming the jingle. Rarely has a class of drugs (in this case, GLP-1s) achieved such widespread attention in popular culture and the media, which has people clamoring for them in every doctor’s office in the nation.
And for good reason. What we know is that the efficacy and safety profile of these medications is substantially better than any weight loss drug in the past, while our obesity epidemic has only ballooned. As organizations committed to sound science and holistic patient care, we are encouraged by the benefits of these new therapies for diabetes. The clinical evidence shows that GLP-1s are highly effective for controlling blood glucose levels among patients living with Type 2 diabetes and certain co-morbidities. GLP-1s may even improve heart health for high-risk patients.
Read the Full Piece in The Health Care Blog
New from ACHP:
- Overcoming Barriers: Transforming Black Maternal Health Through Research Webinar
- PODCAST: ACHP’s Ceci Connolly Joins Managed Healthcare Executive DC Roundtable Podcast
- OP-ED: What Could We Do if GLP-1 Weight Loss Drugs Were Free? Would Our Obesity Epidemic Be Solved for Good?
- ACHP Statement on Final Rule for Medicare Advantage and Part D
- WEBINAR: Medicare Advantage in 2024 and Beyond
- ACHP Joins First Lady Jill Biden and Health Care Leaders to Support Cancer Moonshot Initiative